--- title: "Innovate | 8-K: FY2026 Q1 Revenue: USD 364.8 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286462621.md" datetime: "2026-05-14T20:22:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286462621.md) - [en](https://longbridge.com/en/news/286462621.md) - [zh-HK](https://longbridge.com/zh-HK/news/286462621.md) --- # Innovate | 8-K: FY2026 Q1 Revenue: USD 364.8 M Revenue: As of FY2026 Q1, the actual value is USD 364.8 M. EPS: As of FY2026 Q1, the actual value is USD -1.29. EBIT: As of FY2026 Q1, the actual value is USD 34.5 M. ### Consolidated Financial Metrics INNOVATE Corp. reported consolidated revenue of $364.8 million for the first quarter of 2026, marking a 33.0% increase compared to $274.2 million in the prior year quarter . The net loss attributable to common stockholders and participating preferred stockholders was - $17.2 million, an improvement from - $24.8 million in the prior year quarter, representing a 30.6% reduction in loss . Basic and diluted loss per share attributable to common stockholders was - $1.29, compared to - $1.89 in the prior year quarter, showing a 31.7% reduction in loss . Total Adjusted EBITDA for the quarter was $19.7 million, significantly up from $7.2 million in the prior year quarter, a 173.6% increase . ### Infrastructure Segment - **Revenue**: DBM Global Inc. (DBMG) reported first quarter 2026 revenue of $357.9 million, a 35.1% increase from $264.9 million in the prior year quarter . - **Net Income Attributable to INNOVATE**: The segment reported $9.3 million, compared to $4.6 million for the prior year quarter . - **Adjusted EBITDA**: Increased to $23.0 million from $16.7 million in the prior year quarter . - **Gross Margin**: DBMG’s gross margin was 14.2% in the first quarter, which was a compression of approximately 140 basis points year-over-year . - **Adjusted EBITDA Margin**: DBMG’s Adjusted EBITDA margin was 6.4% in the first quarter, largely consistent with the prior year quarter . - **Backlog**: As of March 31, 2026, DBMG’s reported backlog was $1.6 billion and adjusted backlog was $1.8 billion, compared to $1.7 billion and $1.8 billion respectively, as of December 31, 2025 . ### Life Sciences Segment - **Revenue**: R2 Technologies, Inc. (R2) reported first quarter 2026 revenue of $1.6 million . - **Net Loss Attributable to INNOVATE**: The segment reported - $3.3 million, compared to - $7.6 million in the prior year quarter . - **Adjusted EBITDA**: The segment reported - $2.0 million, compared to - $8.7 million in the prior year quarter . - **Operational Metrics**: R2’s demand for the first quarter reached $2.2 million, and its backlog increased to nearly 160 systems globally post quarter end . R2’s gross system sales outside North America increased 58.6% over the prior year quarter . ### Spectrum Segment - **Revenue**: Broadcasting reported first quarter 2026 revenue of $5.3 million, compared to $6.2 million in the prior year quarter . - **Net Loss Attributable to INNOVATE**: The segment reported - $6.5 million, compared to - $5.4 million in the prior year quarter . - **Adjusted EBITDA**: The segment reported $0.7 million, compared to $1.4 million in the prior year quarter . ### Non-Operating Corporate Segment - **Net Loss Attributable to INNOVATE**: The segment reported - $16.3 million, compared to - $16.1 million in the prior year quarter . - **Adjusted EBITDA**: The segment reported - $2.0 million, compared to - $2.2 million in the prior year quarter . ### Balance Sheet - **Cash and Cash Equivalents**: As of March 31, 2026, INNOVATE Corp. had cash and cash equivalents, excluding restricted cash, of $134.6 million, an increase from $112.1 million as of December 31, 2025 . The Non-Operating Corporate segment had stand-alone cash and cash equivalents of $2.5 million as of March 31, 2026, down from $4.2 million as of December 31, 2025 . ### Outlook / Guidance INNOVATE Corp. anticipates continued strong performance in its Infrastructure segment, driven by a robust pipeline and early progress in building the 2027 backlog, which reinforces confidence in sustained revenue and potential upside . In Life Sciences, MediBeacon is building momentum with key academic medical centers in the United States, and R2 continues its international expansion . The Spectrum segment expects improved performance in the second half of 2026 due to strategic opportunities and collaborative trials, despite near-term advertising pressures . ### Related Stocks - [VATE.US](https://longbridge.com/en/quote/VATE.US.md) ## Related News & Research - [MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation | VATE Stock News](https://longbridge.com/en/news/281183004.md) - [Innovate Q1 2026 Earnings Call Transcript](https://longbridge.com/en/news/286467735.md) - [INNOVATE Q4 revenue jumps 61.7%, net loss narrows](https://longbridge.com/en/news/280683149.md) - [INNOVATE 10-K: Revenue $1,246.0M; Net loss $(64.0) M](https://longbridge.com/en/news/280685780.md)